The Laboratory Role in anti-TNF Biological Therapy Era

Mariapaola Marino, Gian Ludovico Rapaccini, Annunziata Stefanile, Cecilia Napodano, Krizia Pocino, Antonella Di Pino, Umberto Basile, Valentina Grossi, Francesca Gulli, Maria Infantino, Maurizio Benucci, Francesca Li Gobbi, Arianna Damiani, Mariangela Manfredi, Valerio Basile

Research output: Contribution to journalArticle

3 Citations (Scopus)


Along years, the advent of biological therapy widely modified treatment of rheumatic diseases and other disorders. However, many agents may elicit in anti-drug antibodies (ADAbs) upon consecutive infusions, with a loss of response. For the right strategy of a personalized medicine, the therapeutic monitoring of TNF-α inhibitors and ADAbs represents an important effort in diagnostic–therapeutic pathway, to improve overall patient management and favoring an appropriate clinical approach. A raising number of diagnostic tests have been designed to elucidate the efficacy and/or safety of a specific drug or class of drugs for a targeted patient’s group. Our paper reviewed the current understanding of the immunogenicity of biological drugs employed in the treatment of inflammatory diseases underlying the laboratory role.
Original languageEnglish
Pages (from-to)1-16
Number of pages16
JournalImmunological Investigations
Publication statusPublished - 2019


  • TNF
  • adalimumab
  • anti-TNF drugs
  • certolizumab
  • immunogenicity


Dive into the research topics of 'The Laboratory Role in anti-TNF Biological Therapy Era'. Together they form a unique fingerprint.

Cite this